Comparing Entyvio vs Remicade
| Entyvio | Remicade |
|
|---|
| Entyvio (vedolizumab) | Remicade (infliximab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Entyvio is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically instead of... View more |
Prescription only
Prescribed for Ankylosing Spondylitis, Crohn's Disease - Maintenance, Crohn's Disease - Acute, Crohn's Disease, Inflammatory Bowel Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
Crohn's Disease, Maintenance
Popular comparisons
|
|||||||||||||||
| More about Entyvio (vedolizumab) | More about Remicade (infliximab) | ||||||||||||||||
| Generic Status | |||||||||||||||||
|
No lower-cost generic available |
|||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Entyvio has an average rating of 5.7 out of 10 from a total of 121 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 33% reported a negative effect. |
Remicade has an average rating of 7.1 out of 10 from a total of 186 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Side Effects | |||||||||||||||||
|
Common side effects include:
See also: Entyvio side effects in more detail. |
Common side effects include:
See also: Remicade side effects in more detail. |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Entyvio prices |
View all Remicade prices and generic prices |
||||||||||||||||
| Dosage Form(s) Available | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Other infliximab brands include: Avsola, Inflectra, Ixifi, Renflexis | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||||||||||
|
600 hours |
228 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 133 drugs are known to interact with Entyvio:
|
A total of 452 drugs are known to interact with Remicade:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
May 20, 2014 |
August 24, 1998 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.